41. Expression of microRNA-183 in stage II gastric cancer and its association with clinicopathologic features and Ezrin

Objective: To investigate the expression of microRNA-183 (miR-183) in gastric cancer (Stage II GC) and its association with the clinicopathologic features of GC and Ezrin expression.
Methods: Specimens of Stage II GC and normal tissues more than 5 cm away from the tumor tissues were collected from 72 patients. SYBR Green real-time RT-PCR was used to detecte the miR-183 expression, Immunohistochemistry was used to examine the Ezrin protein expression in the tumor tissue. The association of miR-183 expression with the clinicopathologic features of Stage II GC and Ezrin expression were analyzed.
Results: Compared with the non-tumor control samples, the median of relative expression of miR-183 was 0.676 (25th-75th percentile, 0.330-1.253) in the tumor samples, significantly lower than that of the non-tumor control samples (set at 1.000, P<0.05). The lower expression of miR-183 was positively correlated with histological differentiation (0.429 vs. 0.907, P<.05), lymph node positivity (0.507 vs. 0.908, P<0.05) and shorter survival of patients (63.02±3.985 vs. 75.17±3.837, P<0.05). There was a negative correlation between the expression of miR-183 and Ezrin in Stage II GC tissues (r=–0.272, P<0.05).
Conclusions: These results indicate that the miR-183 probably involved in Stage II GC infiltrate metastasis and may become one of the indicator of prognosis, Ezrin is possibly one of targets of miR-183.